Immune checkpoint inhibitors (ICIs) have limited activity in patients with castration-resistant prostate cancer (CRPC). A Nature article demonstrates that androgen receptor (AR) negatively modulates CD8⁺ T cell-driven antitumor immune response and that androgen-axis blockade is a promising therapeutic strategy to improve ICI activity in CRPC.

中文翻译：

---

通过雄激素受体阻断促进抗癌免疫治疗

免疫检查点抑制剂 (ICI) 在去势抵抗性前列腺癌 (CRPC) 患者中的活性有限。一篇Nature文章表明，雄激素受体 (AR) 负调节 CD8 ⁺ T 细胞驱动的抗肿瘤免疫反应，雄激素轴阻断是改善 CRPC 中 ICI 活性的有前景的治疗策略。